Table 1 Patient clinical characteristics and outcomes
Characteristic | No. of Patients (N = 35) | % |
|---|---|---|
Age at diagnosis, years | ||
 30–39 | 11 | 31 |
 40–49 | 13 | 37 |
 50–59 | 4 | 11 |
 60–69 | 7 | 20 |
Race | ||
 Non-Hispanic Caucasian | 32 | 91 |
 Hispanic Caucasian | 1 | 3 |
 Asian/Pacific Islander | 2 | 6 |
Tumor histology | ||
 Ductal | 32 | 91 |
 Lobular | 2 | 6 |
 Other | 1 | 3 |
Clinical stage | ||
 IIA | 9 | 26 |
 IIB | 8 | 23 |
 IIIA | 9 | 26 |
 IIIB | 3 | 9 |
 IIIC | 6 | 17 |
Immunohistochemistry subtype | ||
 Luminal A | 1 | 3 |
 Luminal B | 20 | 57 |
 HER2 | 2 | 6 |
 Triple negative | 12 | 34 |
Residual cancer burden (RCB) | ||
 RCB 0 | 8 | 23 |
 RCB I | 3 | 8 |
 RCB II | 16 | 46 |
 RCB III | 7 | 20 |
 Developed metastases prior to surgery | 1 | 3 |
Long-term outcome | ||
 Recurrences | 7 | 20 |
 Deaths | 4 | 12 |
 Recurrence-free cohort follow up time (years), median (range) | 8.1 (1.1–9.8) |  |